Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
3.550
+0.030 (0.85%)
Mar 31, 2025, 1:23 PM EDT - Market open
Foghorn Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Foghorn Therapeutics stock have an average target of 13.17, with a low estimate of 9.00 and a high estimate of 20. The average target predicts an increase of 270.99% from the current stock price of 3.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Foghorn Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +266.20% | Mar 7, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +181.69% | Jan 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 → $13 | Strong Buy | Reiterates | $20 → $13 | +266.20% | Dec 17, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +294.37% | Dec 16, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $6 → $9 | Hold | Maintains | $6 → $9 | +153.52% | Sep 24, 2024 |
Financial Forecast
Revenue This Year
32.65M
from 22.60M
Increased by 44.46%
Revenue Next Year
40.53M
from 32.65M
Increased by 24.12%
EPS This Year
-1.38
from -1.58
EPS Next Year
-1.08
from -1.38
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.5M | 63.0M | 52.5M | ||
| Avg | 32.7M | 40.5M | 43.0M | ||
| Low | n/a | n/a | 29.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 132.3% | 92.9% | 29.5% | ||
| Avg | 44.5% | 24.1% | 6.0% | ||
| Low | - | - | -27.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.83 | -0.90 | ||
| Avg | -1.38 | -1.08 | -1.44 | ||
| Low | -2.15 | -1.58 | -2.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.